Clinical Trial Update: A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma [Phase 3]

View source ↗

Summary

This Phase 3 trial compares GR1803 Injection against the DPd regimen (daratumumab, pomalidomide, and dexamethasone) in relapsed or refractory multiple myeloma. …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Daratumumab (daratumumab)
• GR1803 Injection (GR1803)
• Pomalidomide (Pomalidomide)

Snippet

Sponsor: Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Conditions: Multiple Myeloma | Phase 3 | Status: RECRUITING